Success Metrics

Clinical Success Rate
75.0%

Based on 9 completed trials

Completion Rate
75%(9/12)
Active Trials
11(26%)
Results Posted
33%(3 trials)
Terminated
3(7%)

Phase Distribution

Ph not_applicable
20
48%
Ph phase_2
11
26%
Ph phase_1
6
14%
Ph phase_3
2
5%

Phase Distribution

6

Early Stage

11

Mid Stage

2

Late Stage

Phase Distribution39 total trials
Phase 1Safety & dosage
6(15.4%)
Phase 2Efficacy & side effects
11(28.2%)
Phase 3Large-scale testing
2(5.1%)
N/ANon-phased studies
20(51.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

64.3%

9 of 14 finished

Non-Completion Rate

35.7%

5 ended early

Currently Active

11

trials recruiting

Total Trials

42

all time

Status Distribution
Active(13)
Completed(9)
Terminated(5)
Other(15)

Detailed Status

unknown15
Completed9
Recruiting8
Active, not recruiting3
Terminated3
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
42
Active
11
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (15.4%)
Phase 211 (28.2%)
Phase 32 (5.1%)
N/A20 (51.3%)

Trials by Status

active_not_recruiting37%
terminated37%
completed921%
recruiting819%
unknown1536%
withdrawn25%
not_yet_recruiting25%

Recent Activity

Clinical Trials (42)

Showing 20 of 42 trialsScroll for more
NCT06363773Not Applicable

A Study to Assess the Ability of Stereotactic Radiotherapy to Restore the Efficacy of Immunotherapy in Patients With Metastatic Cancer.

Recruiting
NCT07437820Not Applicable

Study Comparing Neoadjuvant Versus Adjuvant Stereotactic Radiotherapy of Brain Metastases

Not Yet Recruiting
NCT02984761Not Applicable

Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

Recruiting
NCT03340129Phase 2

Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

Recruiting
NCT07304739Phase 2

Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

Recruiting
NCT05893381Phase 2

Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)

Recruiting
NCT06020066Phase 2

SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI

Active Not Recruiting
NCT03070366Phase 2

Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC

Active Not Recruiting
NCT01290835Not Applicable

Conformal Partial Breast Irradiation With CyberKnife After Resection for Early Stage Breast Cancer

Completed
NCT06665932Not Applicable

Stereotactic Radiotherapy of Prostate Cancer With Reduction of Safety Margins

Recruiting
NCT03769103Phase 2

Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC

Active Not Recruiting
NCT04098432Phase 1

STR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma

Completed
NCT04397978

Local Ablative Therapy for Patients With Multiple (4-10) Brain Metastases

Recruiting
NCT06391008Phase 2

Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer

Not Yet Recruiting
NCT06040177Phase 1

Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Unknown
NCT05973578Not Applicable

Cardiac RadiothErapy for VEntricular Tachycardia

Recruiting
NCT04891471Not Applicable

WHOle Brain Irradiation or STEreotactic Radiosurgery for Five or More Brain Metastases (WHOBI-STER)

Unknown
NCT05641233Phase 1

Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy

Unknown
NCT03199144Phase 2

Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer

Withdrawn
NCT03286023

Stereotactic Radiotherapy for Brain Metastases

Unknown

Drug Details

Intervention Type
RADIATION
Total Trials
42